Cravath represented Mylan N.V. in connection with its €3 billion Reg. S senior floating and fixed rate debt offering. Mylan N.V. is a leading global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The notes were listed on the Irish Stock Exchange. The transaction closed on November 22, 2016.
The Cravath team included partners William V. Fogg and Johnny G. Skumpija and associates Benjamin S. Persina, Martin P. Pepeljugoski and Jin‑Kyu Baek.